# Cogent Biosciences (COGT) — Earnings

COGT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cogt/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$0.50 |
| EPS estimate | −$0.52 |
| EPS surprise | +3.19% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Nov 3, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm) |

The most recent quarter in the table is Q3 2025, which Cogent Biosciences reported on November 3, 2025. The loss was $0.50 per share, slightly better than the expected loss of $0.52, a 3.19% beat. No revenue was reported and no revenue estimate was given. A year earlier, in Q3 2024, the loss was $0.64 per share.

Every one of the 20 quarters in the table was a loss. Full-year losses were $1.85 per share in 2021, $2.45 in 2022, $2.40 in 2023 and $2.46 in 2024. The first three quarters of 2025 add up to a loss of $1.67, narrower than the $1.85 of the same period in 2024. Since Q4 2021, quarterly losses have stayed between $0.50 and $0.71 per share. The largest loss in the table, $6.06, came in Q4 2020, the oldest row. Cogent beat the EPS estimate only 5 times in 20 quarters.

The table has no results after Q3 2025. In past years, Cogent reported fourth-quarter results between late February and mid-March, and third-quarter results between early and mid-November. The next update to the table will show whether losses kept narrowing after Q3 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 3, 2025 | −$0.52 | −$0.50 | 3.19% | — | — |
| Q2 2025 | Aug 5, 2025 | −$0.59 | −$0.53 | 9.71% | — | — |
| Q1 2025 | May 6, 2025 | −$0.59 | −$0.64 | -7.17% | — | — |
| Q4 2024 | Feb 25, 2025 | −$0.61 | −$0.61 | -0.25% | — | — |
| Q3 2024 | Nov 12, 2024 | −$0.57 | −$0.64 | -13.03% | — | — |
| Q2 2024 | Aug 6, 2024 | −$0.56 | −$0.59 | -5.92% | — | — |
| Q1 2024 | May 7, 2024 | −$0.51 | −$0.62 | -20.51% | — | — |
| Q4 2023 | Feb 26, 2024 | −$0.56 | −$0.63 | -11.82% | — | — |
| Q3 2023 | Nov 2, 2023 | −$0.50 | −$0.64 | -27.72% | — | — |
| Q2 2023 | Aug 8, 2023 | −$0.54 | −$0.59 | -8.38% | — | — |
| Q1 2023 | May 9, 2023 | −$0.57 | −$0.54 | 5.48% | — | — |
| Q4 2022 | Mar 14, 2023 | −$0.52 | −$0.56 | -8.30% | — | — |
| Q3 2022 | Nov 14, 2022 | −$0.51 | −$0.50 | 2.59% | — | — |
| Q2 2022 | Aug 9, 2022 | −$0.66 | −$0.71 | -8.12% | — | — |
| Q1 2022 | May 10, 2022 | −$0.61 | −$0.68 | -12.40% | — | — |
| Q4 2021 | Mar 15, 2022 | −$0.52 | −$0.60 | -14.50% | — | — |
| Q3 2021 | Nov 10, 2021 | −$0.45 | −$0.48 | -6.67% | — | — |
| Q2 2021 | Aug 16, 2021 | −$0.36 | −$0.43 | -20.55% | — | — |
| Q1 2021 | May 12, 2021 | −$0.42 | −$0.34 | 18.07% | — | — |
| Q4 2020 | Mar 16, 2021 | −$0.51 | −$6.06 | -1088.24% | $50,000.00 | — |

## Frequently Asked Questions

### When did Cogent Biosciences (COGT) last report earnings?

Cogent Biosciences last reported on Nov 3, 2025, covering fiscal Q3 2025.

### Did COGT beat earnings estimates?

Yes. Cogent Biosciences reported EPS of −$0.50 for Q3 2025 against a −$0.52 estimate — a 3.19% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).